327 related articles for article (PubMed ID: 34608615)
1. Precision Therapy for Epilepsy Related to Brain Malformations.
D'Gama AM; Poduri A
Neurotherapeutics; 2021 Jul; 18(3):1548-1563. PubMed ID: 34608615
[TBL] [Abstract][Full Text] [Related]
2. mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations.
Auvin S; Baulac S
Rev Neurol (Paris); 2023 Apr; 179(4):337-344. PubMed ID: 36906459
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
Jeong A; Wong M
J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
[TBL] [Abstract][Full Text] [Related]
4. mTOR signaling in epilepsy: insights from malformations of cortical development.
Crino PB
Cold Spring Harb Perspect Med; 2015 Apr; 5(4):. PubMed ID: 25833943
[TBL] [Abstract][Full Text] [Related]
5. Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy.
Pelorosso C; Watrin F; Conti V; Buhler E; Gelot A; Yang X; Mei D; McEvoy-Venneri J; Manent JB; Cetica V; Ball LL; Buccoliero AM; Vinck A; Barba C; Gleeson JG; Guerrini R; Represa A
Hum Mol Genet; 2019 Nov; 28(22):3755-3765. PubMed ID: 31411685
[TBL] [Abstract][Full Text] [Related]
6. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
7. Cortical Dysplasia and the mTOR Pathway: How the Study of Human Brain Tissue Has Led to Insights into Epileptogenesis.
Lee WS; Baldassari S; Stephenson SEM; Lockhart PJ; Baulac S; Leventer RJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163267
[TBL] [Abstract][Full Text] [Related]
8. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the genetic basis of focal cortical dysplasia: a large cohort study.
Baldassari S; Ribierre T; Marsan E; Adle-Biassette H; Ferrand-Sorbets S; Bulteau C; Dorison N; Fohlen M; Polivka M; Weckhuysen S; Dorfmüller G; Chipaux M; Baulac S
Acta Neuropathol; 2019 Dec; 138(6):885-900. PubMed ID: 31444548
[TBL] [Abstract][Full Text] [Related]
10. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
Wong M
Exp Neurol; 2013 Jun; 244():22-6. PubMed ID: 22015915
[TBL] [Abstract][Full Text] [Related]
12. Focal malformations of cortical development: new vistas for molecular pathogenesis.
Lim KC; Crino PB
Neuroscience; 2013 Nov; 252():262-76. PubMed ID: 23892008
[TBL] [Abstract][Full Text] [Related]
13. Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism.
Mirzaa GM; Campbell CD; Solovieff N; Goold C; Jansen LA; Menon S; Timms AE; Conti V; Biag JD; Adams C; Boyle EA; Collins S; Ishak G; Poliachik S; Girisha KM; Yeung KS; Chung BHY; Rahikkala E; Gunter SA; McDaniel SS; Macmurdo CF; Bernstein JA; Martin B; Leary R; Mahan S; Liu S; Weaver M; Doerschner M; Jhangiani S; Muzny DM; Boerwinkle E; Gibbs RA; Lupski JR; Shendure J; Saneto RP; Novotny EJ; Wilson CJ; Sellers WR; Morrissey M; Hevner RF; Ojemann JG; Guerrini R; Murphy LO; Winckler W; Dobyns WB
JAMA Neurol; 2016 Jul; 73(7):836-845. PubMed ID: 27159400
[TBL] [Abstract][Full Text] [Related]
14. GATORopathies: The role of amino acid regulatory gene mutations in epilepsy and cortical malformations.
Iffland PH; Carson V; Bordey A; Crino PB
Epilepsia; 2019 Nov; 60(11):2163-2173. PubMed ID: 31625153
[TBL] [Abstract][Full Text] [Related]
15. mTOR dysregulation and tuberous sclerosis-related epilepsy.
Curatolo P; Moavero R; van Scheppingen J; Aronica E
Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging and genetic characteristics of malformation of cortical development due to mTOR pathway dysregulation: clues for the epileptogenic lesions and indications for epilepsy surgery.
Specchio N; Pepi C; De Palma L; Trivisano M; Vigevano F; Curatolo P
Expert Rev Neurother; 2021 Nov; 21(11):1333-1345. PubMed ID: 33754929
[No Abstract] [Full Text] [Related]
17. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia.
D'Gama AM; Geng Y; Couto JA; Martin B; Boyle EA; LaCoursiere CM; Hossain A; Hatem NE; Barry BJ; Kwiatkowski DJ; Vinters HV; Barkovich AJ; Shendure J; Mathern GW; Walsh CA; Poduri A
Ann Neurol; 2015 Apr; 77(4):720-5. PubMed ID: 25599672
[TBL] [Abstract][Full Text] [Related]
18. Pathogenetic mechanisms of focal cortical dysplasia.
Marin-Valencia I; Guerrini R; Gleeson JG
Epilepsia; 2014 Jul; 55(7):970-8. PubMed ID: 24861491
[TBL] [Abstract][Full Text] [Related]
19. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia.
Leitner DF; Kanshin E; Askenazi M; Siu Y; Friedman D; Devore S; Jones D; Ueberheide B; Wisniewski T; Devinsky O
PLoS One; 2022; 17(5):e0268597. PubMed ID: 35587487
[TBL] [Abstract][Full Text] [Related]
20. mTOR pathway: Insights into an established pathway for brain mosaicism in epilepsy.
Gerasimenko A; Baldassari S; Baulac S
Neurobiol Dis; 2023 Jun; 182():106144. PubMed ID: 37149062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
